Objective: This study aimed to determine the relation between titres of anti- antibody and rheumatoid arthritis (RA) HLA-DRB1 susceptibility region associated with shared epitope (SE) using the Gregersen's and de Vries's classification methods.
Material And Methods: In this cross-sectional study, results of immunoglobulin G1 (IgG1) and immunoglobulin G2 (IgG2) anti-P. gingivalis antibodies, anti-citrullinated protein antibodies (ACPA), diagnosis for RA, and periodontal disease (PD), and a genetic study of the HLA DRB1 region were obtained from 50 patients with RA and 50 control individuals.
Results: Anti- antibody levels and PD parameters were similar in control and RA groups. Anti- antibodies were not associated with SE or ACPA. There was no association between ACPA and SE. However, de Vries' classification in RA patients revealed an association between the HLA DRB1 neutral alleles and higher titres of anti- antibodies as follows: IgG1 anti- ≥ 1:400 ( = .039); IgG2 anti- ≥ 1:400 with neutral/neutral genotype (N/N), being exclusive for RA ( = .008); and IgG2 anti- ≥ 1:200 and N/N ( = .016).
Conclusions: Although no association was found between SE and anti- antibodies; according to the de Vries' classification, there was an existing association between HLA DRB1 neutral alleles, with high titres of IgG anti- antibodies for RA, focussing on novel associations between and RA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00016357.2021.1959053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary fibrosis as the sole manifestation of anti-Ku antibody positivity in the absence of myositis: A case report.
Respir Med Case Rep
January 2025
Department of Rheumatology of Lucania - UOSD of Rheumatology, "Madonna delle Grazie" Hospital, Matera, Italy.
Background: Anti-Ku antibodies are autoantibodies directed against the Ku protein complex involved in DNA repair. They are typically associated with overlap syndromes featuring polymyositis and systemic sclerosis. Isolated pulmonary involvement without myositis is exceedingly rare.
View Article and Find Full Text PDFInterferon activation in bone marrow long-lived plasma cells in systemic lupus erythematosus.
Front Immunol
January 2025
Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, United States.
While durable antibody responses from long-lived plasma cell (LLPC) populations are important for protection against pathogens, LLPC may be harmful if they produce antibodies against self-proteins or self-nuclear antigens as occurs in autoimmune diseases such as systemic lupus erythematosus (SLE). Thus, the elimination of autoreactive LLPC may improve the treatment of antibody-driven autoimmune diseases. However, LLPC remain a challenging therapeutic target.
View Article and Find Full Text PDFHyperhomocysteinemia-associated Thrombosis in Patients With Pernicious Anemia.
J Community Hosp Intern Med Perspect
January 2025
Section of Benign Hematology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA.
Introduction: Cobalamin deficiency (CD) due to pernicious anemia (PA) leads to hyperhomocystinemia, a risk factor for thrombosis. However, the clinical presentations and outcomes of hyperhomocystinemia-associated thrombosis (HAT) are not fully understood.
Methods: We undertook a literature search using PUBMED, SCOPUS and WEB OF SCIENCE databases for the terms "pernicious anemia AND thrombosis", "pernicious anemia AND embolism", "pernicious anemia AND thromboembolism", "autoimmune gastritis AND thrombosis", "autoimmune gastritis AND embolism", "autoimmune gastritis AND thromboembolism" through January 2024 and reviewed the published literature.
Infliximab Precision Dosing in Inflammatory Bowel Disease (IBD) Patients: A Review of Current Literature.
Cureus
December 2024
Gastroenterology, St Mark's Hospital and Academic Institute, London, GBR.
The therapeutic failure of infliximab therapy remains a challenge in patients with inflammatory bowel disease (IBD), and dose optimization is often required. Accelerated or intensified regimes showed value in treating patients in the acute setting with high CRP or low albumin levels, which are suggested by recent guidelines; however, evidence is weak. Therapeutic drug monitoring (TDM), with anti-tumor necrosis factor-alpha (TNF-α) trough levels and antibodies, showed value during maintenance therapy, but not in induction and can guide clinical decisions in patients that might be undertreated with the standard dosing regimen.
View Article and Find Full Text PDFRapidly Progressive Glomerulonephritis Associated With Anti-glomerular Basement Membrane Disease: A Rare Diagnosis.
Cureus
December 2024
Medicine, Faculdade de Medicina da Universidade do Porto (FMUP), Porto, PRT.
Anti-glomerular basement membrane disease is a rare small vessel vasculitis caused by the deposition of immunoglobulin G (IgG) autoantibodies in the basement membrane of glomerular capillaries and lung alveoli, leading to rapidly progressive renal failure and/or alveolar hemorrhage. We report the case of an 83-year-old female patient presenting with uremic symptoms, rapidly progressive kidney failure, and a high titer of anti-glomerular basement membrane antibodies. Given the urgent need for kidney replacement therapy, the substantial fibrosis and glomerular scarring observed in the kidney biopsy suggesting a chronic process, and the absence of pulmonary involvement, neither immunosuppressive treatment nor plasmapheresis was initiated, since a low likelihood of a favorable response to these interventions was expected.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!